Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 16/20 | 0.60 |
| ▸ | ADORA1 | P30542 | 15/20 | 0.60 |
| ▸ | FGR | P09769 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.42 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.42 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13239655 | 0.79 | ADORA2A (0.66) | ADORA2AADORA1FGRPIM1MAOA | |
| SCHEMBL1378743 | 0.76 | ADORA2A (1.00) | ADORA2AADORA1 | |
| SCHEMBL8289410 | 0.75 | ADORA2A (0.60) | ADORA2AADORA1FGRPIM1MAOA | |
| SCHEMBL1380846 | 0.71 | ADORA2A (0.71) | ADORA2AADORA1 | |
| SCHEMBL1377629 | 0.70 | ADORA2A (1.00) | ADORA2AADORA1ADORA2B | |
| SCHEMBL1378021 | 0.70 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BHRH3ALDH1A1 | |
| SCHEMBL4878240 | 0.69 | HRH4 (0.52) | ADORA2AADORA1MAOAHRH3ALDH1A1 | |
| SCHEMBL4876209 | 0.69 | THRB (0.45) | ADORA2AADORA1MAOAALDH1A1 | |
| SCHEMBL4574773 | 0.69 | ADORA2A (0.39) | ADORA2AADORA1MAOAHRH3ALDH1A1 | |
| SCHEMBL4869094 | 0.68 | HRH3 (0.41) | ADORA2AADORA1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7759356-B2 | Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods | JANSSEN PHARMACEUTICA, N.V. (BE) | 2010-07-20 | — | — | US | disclosed |
| US-7759356-B2 | Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods | JANSSEN PHARMACEUTICA, N.V. (BE) | 2010-07-20 | — | — | US | disclosed |
| US-7754730-B2 | Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2010-07-13 | — | — | US | disclosed |
| US-7754730-B2 | Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2010-07-13 | — | — | US | disclosed |
| EP-1673354-B1 | ARYLINDENOPYRIDINES AND ARYLINDENOPYRIMIDINES AND THEIR USE AS ADENOSINE A2A RECEPTOR ANTAGONISTS | ORTHO MCNEIL PHARM INC (US) | 2009-04-22 | — | — | EP | disclosed |
| US-20090054429-A1 | ARYLINDENOPYRIDINES AND ARYLINDENOPYRIMIDINES AND RELATED THERAPEUTIC AND PROPHYLACTIC METHODS | JANSSEN PHARMACEUTICA NV (BE) | 2009-02-26 | — | — | US | disclosed |
| US-20090054429-A1 | ARYLINDENOPYRIDINES AND ARYLINDENOPYRIMIDINES AND RELATED THERAPEUTIC AND PROPHYLACTIC METHODS | JANSSEN PHARMACEUTICA NV (BE) | 2009-02-26 | — | — | US | disclosed |
| US-7468373-B2 | Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-7468373-B2 | Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-7345052-B2 | Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-7345052-B2 | Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-20070155760-A1 | ARYLINDENOPYRIDINES AND ARYLINDENOPYRIMIDINES AND RELATED THERAPEUTIC AND PROPHYLACTIC METHODS | JANSSEN PHARMACEUTICA NV (BE) | 2007-07-05 | — | — | US | disclosed |
| US-20070155760-A1 | ARYLINDENOPYRIDINES AND ARYLINDENOPYRIMIDINES AND RELATED THERAPEUTIC AND PROPHYLACTIC METHODS | JANSSEN PHARMACEUTICA NV (BE) | 2007-07-05 | — | — | US | disclosed |
| US-20070155760-A1 | ARYLINDENOPYRIDINES AND ARYLINDENOPYRIMIDINES AND RELATED THERAPEUTIC AND PROPHYLACTIC METHODS | JANSSEN PHARMACEUTICA NV (BE) | 2007-07-05 | — | — | US | disclosed |
| US-20050267142-A1 | Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods | HEINTZELMAN GEOFFREY R | 2005-12-01 | — | — | US | disclosed |
| US-20050267138-A1 | Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods | HEINTZELMAN GEOFFREY R | 2005-12-01 | — | — | US | disclosed |
| US-20050267139-A1 | Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods | HEINTZELMAN GEOFFREY R | 2005-12-01 | — | — | US | disclosed |
| US-20050239810-A1 | Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods | HEINTZELMAN GEOFFREY R | 2005-10-27 | — | — | US | disclosed |
| US-20050239812-A1 | Adenosine A2a receptors antagonist; 9H-indeno[2,1-c]pyridine-4-carboxylic acid, 3-amino-1-furan-2-yl-9-oxo-, 2-dimethylamino-ethyl ester; neurodegenerative and movement disease, as Parkinson's; improves binding affinity of Dopamine D2 agonist to their receptors | HEINTZELMAN GEOFFREY R | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239810-A1 | Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA1 2/4885FGR 1079/4885 |
| US-20070155760-A1 | ARYLINDENOPYRIDINES AND ARYLINDENOPYRIMIDINES AND RELATED THERAPEUTIC AND PROPHYLACTIC METHODS | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA1 2/4885FGR 1021/4885 |
| US-20050267139-A1 | Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA1 2/4885FGR 1079/4885 |
| US-20050267138-A1 | Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA1 2/4885FGR 1021/4885 |
| US-20050239812-A1 | Adenosine A2a receptors antagonist; 9H-indeno[2,1-c]pyridine-4-carboxylic acid, 3-amino-1-furan-2-yl-9-oxo-, 2-dimethylamino-ethyl ester; neurodegenerative and movement disease, as Parkinson's; improves binding affinity of Dopamine D2 agonist to their receptors | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA1 3/4885FGR 2644/4885 |
| US-20090054429-A1 | ARYLINDENOPYRIDINES AND ARYLINDENOPYRIMIDINES AND RELATED THERAPEUTIC AND PROPHYLACTIC METHODS | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA1 2/4885FGR 1021/4885 |
| US-20050267142-A1 | Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA1 2/4885FGR 1021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.